cyrilzakka/clinical-trials huggingface dataset:
Serial Therapeutic and Antifungal Monitoring Protocol

The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture.

This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.

One blood culture and one set of T2clinical specimens will be collected at specified intervals to monitor the clearance of Candida infection from the bloodstream.

Each T2 result will be compared to the companion blood culture result. The comparison will determine if the presence of antifungal therapy inhibits blood culture and leads to an incidence of blood culture false negative test results. The T2 result, which is not impacted by the presence of antifungal therapy, can show that the pathogen is still present for some additional period of time.

Eligibility Criteria:
Inclusion Criteria:

* Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them.
* Subject is between 18-95 years of age
* Subject has a blood culture result that is positive for yeast within 36 hours of enrollment

Exclusion Criteria:

* Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study
* All T2 Bio individual clinical research specimens contain \< 3 ml of blood
* Use of any novel (i.e. not commercially available) drug compound within 30 days prior to the collection of T2 Bio blood specimens.
Outcomes of Trasversus Abdominis Release for Complex Abdominal Wall Hernia

This multicenter retrospective study analyzed data from 308 patients who underwent open Posterior Component separation with Trasversus release for primary or recurrent complex abdominal hernias between 2015 and 2020. The primary endpoint was the rate of Hernia Recurrence and Mesh Bulging at 3, 6, 12, 24, and 36 months. Secondary outcomes included surgical site events and were assessed using the Pain scale.

Study design This study is reported according to the STROBE statement for cohort studies A retrospective multicentric study was conducted to analyze the surgical outcomes of patients undergoing open with Posterior Component separation with Trasversus release for inisional hernia. It was conducted according to the ethical principles stated in the Declaration of Helsinki. Written informed consent was obtained from all subjects.

Study setting and study population From January 2015 and May 2020, all the patients affected by primary or recurrent complex abdominal hernias undergoing open Posterior Component separation with Trasversus release referring to 6 centers, were considered for enrollment in the study. Inclusion criteria were age ≥16 years, primary or recurrent complex abdominal hernias with more than \>10 cm midline defects Exclusion criteria were follow-up data lower than 36 months, patients with a stoma for whom closure was not planned during the abdominal hernia repair

Eligibility Criteria:
Inclusion Criteria:

* age ≥16 years,
* primary or recurrent complex abdominal hernias with more than \>10 cm midline defects

Exclusion Criteria:

* follow-up data lower than 36-months, patients with a stoma for whom closure was not planned during the abdominal hernia repair
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

The study evaluates safety and efficacy of vaniprevir (MK7009), when administered with Pegylated-Interferon (peg-IFN) and Ribavirin, in Japanese patients with Hepatitis C infection. The primary hypotheses are that 1.) the proportion of patients achieving rapid viral response (RVR) in one or more of the vaniprevir treatment groups is superior to that in the placebo group, when each is administered concomitantly with pegylated interferon (peg-IFN) α-2a and ribavirin; and 2.) vaniprevir at the studied doses is well tolerated compared with placebo, when each is administered concomitantly with peg-IFN α-2a and ribavirin for 28 days.


Eligibility Criteria:
Inclusion Criteria:

* Has chronic genotype 1 Hepatitis C infection

Exclusion Criteria:

* Has not tolerated previous course of peg-IFN and ribavirin
* Has HIV
* Has Hepatitis B
* Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and ribavirin
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
   2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion Criteria:

None.
Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

"This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis.

Positive results from COVIDSeq Test using saliva and/or the comparator EUA test will be provided to subjects so participants can be referred for further evaluation (outside the study). No medical treatment, guidance on treatment decisions, nor medical care will be provided. "


Eligibility Criteria:
Subject Inclusion Criteria:

An individual must meet the criteria below to be eligible.

* Individual is Illumina US personnel (eg, employee, contractor, consultant) and was invited to participate in the study.
* Individual is 18 years or older at the time of consent.
* Individual is feeling well and, at the time of consent or specimen collection, does not have any of the following symptoms of COVID-19: cough, shortness of breath or difficulty breathing, fatigue, fever or chills, muscle or body aches, headache, sore throat, new loss of taste or smell, congestion or runny nose, nausea or vomiting, or diarrhea. \[1\]
* Individual is willing to participate in study procedures and able to provide written informed consent in the English language.

Subject Exclusion Criteria:

An individual cannot meet the below criteria.

* Individual is confirmed to have COVID-19 and continues to require home isolation in accordance with current CDC guidelines at the time of consent or specimen collection.
* Individual is asymptomatic but suspected to have COVID-19 due to recent close contact (as currently defined by the CDC) with a person with COVID-19 and continues to require quarantine in accordance with current CDC guidelines at the time of consent or specimen collection. \[4\]
* Individual had symptoms of COVID-19 less than 10 days before time of consent or less than 10 days before time of any subsequent specimen collection visit."
Magnetic Resonance Fingerprinting for Preoperative Evaluation of Lymphovascular Space Invasion in Early Stage Cervical Cancer

The aim of this observational prospective study is to investigate the role of Magnetic Resonance Fingerprinting in preoperative assessment of early cervical cancer


Eligibility Criteria:
Inclusion Criteria:

* Patients with biopsy-proven cervical cancer FIGO stage IA-IIA undergoing surgery;
* Women aged \>18 years old;
* Signed Informed Consent.

Exclusion Criteria:

* Concurrent malignancies at other sites;
* Previous history of neoplasm;
* Refusal to sign written informed consent
The Need for Luteal Support in NC-FET

The investigators are going to examine prospectively the need of luteal support after NC-FET.

The investigators are going to examine retroprospectively the need of luteal support after NC-FET in IVF cycle. One arm will receive luteal support after NC FET with vaginal tablet of Endometrin 100 mg twice a day after ET. The second arm will not. We are going to evaluate the pregnancy and implantation rate.

Eligibility Criteria:
Inclusion Criteria:

* Women under 39 years old, regular menstruation going through IVF NC-FET

Exclusion Criteria:

* NO
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.


Eligibility Criteria:
Inclusion Criteria:

* Histopathologic or cytologic diagnosis of pancreatic adenocarcinoma, or adenosquamous cancer, or any non-neuroendocrine primary pancreas variant, including acinar cancer.
* De novo or recurrent diagnosis of previously untreated stage IV PDAC with intent to receive FOLFIRINOX/mFOLFIRINOX.
* ECOG 0-2.
* No use of pancreatic enzyme replacement therapy within prior 2 weeks.
* Patients with biliary obstruction are eligible provided biliary stenting has or will occur before treatment with FOLFIRINOX.
* Ability to understand and the willingness to sign an informed consent document.
* Ability to swallow capsules.
* Age ≥18 years.
* Anticipated life expectancy of at least 6 months.

Exclusion Criteria:

* Chronic illness associated with malabsorption (celiac disease, cystic fibrosis, chronic pancreatitis, Crohn's disease).
* Fibrosing colonopathy.
* Prior history of surgical resection of the pancreas or gastric bypass.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Pancrelipase.
* Patients cannot receive radiation, IRE, or other localized therapy directed to the pancreas while on study.
MOD&JEU: Moderators of Online Gambling, How Effective?

Prevalence of problem gambling is estimated about 1-3% of the general adult population. This percentage increases to 5% when talking about online gambling. In France, the market for online gambling was recently opened up to competition and regulation (May 2010), including poker and sports/horse races betting, but excluding for the moment casino games. Recent international studies show that legalizing online gambling led to an increase of practices, including problem gambling.

In France, the law stipulates the establishment of moderators of online gambling, to prevent excessive gambling practices. The Regulatory Authority of Online Games (ARJEL) guarantees the implementation of these moderators. However, no evaluation of the effectiveness of these moderators is planned.

Therefore the investigators propose to conduct an experimental study about online gambling. The objective will be to evaluate the effectiveness of four kinds of moderators, some already legislated, but not evaluated, and others offered by the investigators team. Proposals for amending legislation will be made according the results of this study.


Eligibility Criteria:
Inclusion Criteria:

* Adult
* French people, living around Nantes
* Giving their consent for access to their gambling account
* User of a gambling site approved by the ARJEL, with an active account
* Regular gambler (gambling at least once a week, since at least 3 months)

Exclusion Criteria:

* Age under 18 and over 65
* Excessive gamblers (CPGI \> 8) or gambler seeking treatment
* Protected persons (pregnant women, being under protection measures)
* Overindebtedness
* Psychiatric or cognitive major dysfunctions
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of locally advanced or metastatic HCC, obtained by histology/cytology (on a prior tumor biopsy) or by imaging with serum α-fetoprotein (AFP) ≥400 ng/mL.
* All patients must provide at least 1 archival tumor specimen. If archival tumor specimen is no longer available, de novo tumor biopsy will be required during screening.
* HCC not amenable to local therapy.
* Measurable disease according to RECIST v. 1.1.
* Child Pugh Class A disease.
* BCLC stage B or C disease.
* No evidence of uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart.
* ECOG performance status 0 or 1.
* Adequate bone marrow function, renal and liver functions
* Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) as assessed by multigated acquisition (MUGA) scan or echocardiogram (ECHO).

Exclusion Criteria:

* Prior systemic treatment for advanced HCC, including prior treatment with approved or investigational drugs.
* Any prior locoregional therapy within 4 weeks and radiotherapy or surgical procedure within 2 weeks (4 weeks for major surgery) of enrollment.
* Patients with known symptomatic brain metastases requiring steroids.
* Presence of hepatic encephalopathy (ie, Child Pugh score of 2 or 3) and/or clinically relevant ascites (ie, Child Pugh score of 3).
* Presence of main portal vein invasion by HCC.
* Any of the following within the 12 months prior to enrollment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, LVEF less than LLN, clinically significant pericardial effusion, cerebrovascular accident, transient ischemic attack.
* Active infection requiring systemic therapy except for hepatitis C virus (HCV) and hepatitis B virus (HBV).
E-learning to Prevent Drug Errors in Anesthesia

The purpose of this observational study is to assess the efficiency of an e-learning in order to put into practice some preventive measures to avoid medication errors during anesthesia.

Before the study, the investigators selected 15 preventive measures to avoid medication errors during anesthesia. These measures were learned to the entire anesthesia team (nurse, resident and anesthesiologist) during conventional meetings. An initial evaluation of the application of these measures will be carried out before the introduction of e-learning. This assessment will be conducted by nurses without the knowledge of the anesthetic team evaluated. After this initial evaluation, e-learning will be broadcast on the hospital intranet. Then a second evaluation of the application of the preventive measures will be carried out 6 month and 1 year after the introduction of e-learning.

Eligibility Criteria:
Inclusion criteria:

* patient undergoing regional and/or general anesthesia

Exclusion criteria:

* only sedation
Hard and Soft Tissue Changes Following Vestibular Socket Preservation Versus Ice Cream Cone Technique for Management of Defective Fresh Extraction Sockets in the Esthetic Zone: A Randomized Clinical Trial

Evaluation of hard and soft tissue changes following vestibular socket preservation versus ice cream cone technique for management of defective fresh extraction sockets in the esthetic zone.

The aim of this randomized clinical trial is to assess the volumetric and radiographic ridge contour changes following alveolar ridge preservation using Vestibular socket preservation in patient with type II fresh extraction sockets, versus ice cream cone technique.

In patients needing extraction in anterior maxilla with type II sockets, there will be no difference between the Vestibular socket preservation and ice cream cone technique regarding the changes in alveolar ridge contour.

Eligibility Criteria:
Inclusion Criteria:

* Adults from the age of 18 - 40 years
* Patients with non-restorable maxillary teeth/tooth indicated for extraction in the area from 2nd premolar to 2nd premolar
* Type II sockets will be selected as revealed by Cone beam computed tomography (CBCT).
* Intact gingival tissue with at least 2mm keratinized tissue
* Absence of any systemic disease or drugs that contraindicate oral surgery using Modified
* Cornell Medical Index .
* Patients accepts to provide informed consent

Exclusion Criteria:

* Pregnant and lactating females.
* Smokers as smoking is a contraindication for any plastic periodontal surgery.
* Patients with BOP\>15%.
* Patients with periodontal diseases .
* Handicapped and mentally retarded patients.
* Patients undergoing radiotherapy.
* Presence of systemic disease that would affect wound healing.
* Presence of active infection with soft tissue communication.
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

The main purposes of this study are to determine:

* The safety of tirzepatide and any side effects that might be associated with it.
* How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
* How tirzepatide affects the levels of blood sugar.

This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part.

This study is for research purposes only, and is not intended to treat any medical condition.


Eligibility Criteria:
Inclusion Criteria:

* Healthy participants (Parts A and B) and participants with T2DM diagnosed at least 1 year before enrollment (Part C)
* Have a screening body mass index (BMI) of greater than 18.5 and less than or equal to 40.0 kilograms per meter squared (kg/m²), inclusive
* Participants with T2DM (Part C only): have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin for at least 30 days or sulfonylureas). Participants receiving sulfonylureas may participate only if this treatment is stopped for at least 6 weeks before dosing with study drug

Exclusion Criteria:

* Have known allergies to tirzepatide, glucagon-like peptide (GLP)-1 analogs, or related compounds
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
* Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase (greater than 2-fold the upper limit of normal \[ULN\]) or gastrointestinal (GI) disorder (for example, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-IV inhibitors

Participants with T2DM (Part C only)

* Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms

All Study Participants (Parts B and C only)

* have known allergies to tirzepatide, GLP-1 analogs, or related compounds, or acetaminophen
Direct Anterior Approach Versus Mini Posterior Approach Versous Lateral Approach for Displaced Femoral Neck Fractures

In general, hip fractures in the elderly are associated with a high one year-mortality up to 36 %. Apart from choosing the proper treatment, optimizing the surgical technique itself offers options to improve the outcome. Early mobilization after hip hemi¬arthroplasty correlates with improved ambulation, reduced need for assisted transfers, and less use of extended care facilities after hospital discharge.

Nowadays, in order to reduce soft tissue damage and gain quicker postoperative recovery and faster rehabilitation, various MIS techniques have been proposed. Two of these techniques are the mini posterior approach and the mini direct anterior approach. The direct anterior approach was developed as a true internervous and intermuscular surgical approach with proposed benefits of faster recovery, quicker return to function, and less pain. In theory, the direct anterior approach should cause less tissue damage than mini posterior approach, as it is performed through a plane between neurlogical tissue and intermuscular plane without muscle transection.

The aim of this study is to evaluate the clinical and radiological outcomes of the direct anterior approach for bipolar head endoprosthetic hemiarthroplasty in patients with displaced femoral neck fractures in comparison with the mini posterior approach and the traditional lateral approach, for the treatment of the same fractures. The investigators hypothesized that patients undergoing the direct anterior approach would have better clinical and radiological results in comparison with the mini posterior and lateral approach.


Eligibility Criteria:
Inclusion Criteria:

* Consecutive patients undergoing hip fracture surgery for displaced femoral neck fractures (Garden 3 and 4 fractures) and treated by cemented hemiarthroplasty will be included in the study. Patients must have the ability to give informed consent or a legal guardian is available.

Exclusion Criteria:

* The exclusion criteria include open or pathological fractures, re-fractures, infection, concomitant injuries of the ipsi- or contralateral leg or upper limb, skin diseases in the area of proposed incisions, patients that are mentally incapable of understanding the consequences of the study and reduced compliance.